what is vitrogro?, page-15

I too suspect we are being had - but here goes.

Small biotechs with limited research $$ have to start their quest for commercialisation somewhere - Venous and Diabetic ulcers are relatively similar, huge in number and high profile medical condition. So why not start there.

In Dec2010 presentation on EU trials there are many potential targets stated - previously mentioned on this thread. TIS doesn't have the resources to actively pursue these opportunities at this time - but we can be assured they will be discussed in current round of commercialisation discussions.

Many of these will be dealt with through off-label usage of VitroGro rather than specific trials - but need to get a high profile success (eg ulcer healing) first.

Then - there's usage as a medium for growth of stem cells and also potential in treatment of various cancers.

I am not a biochemist - dyor